<DOC>
	<DOCNO>NCT02337738</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety TVP-1012 ( 0.5 mg 1 mg/day ) add-on levodopa Japanese participant Parkinson 's disease wearing-off phenomenon .</brief_summary>
	<brief_title>A Phase 2/3 Study TVP-1012 0.5 mg 1 mg Levodopa Treated Parkinson 's Disease Participants</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo-controlled , parallel group , phase 2/3 study evaluate efficacy safety TVP-1012 add-on levodopa Japanese participant Parkinson 's disease wearing-off phenomenon . The study period consist 28-week trial period . The participant fulfill inclusion criterion meet exclusion criterion enrol , randomize 1:1:1 ratio 0.5 mg TVP-1012 , 1 mg TVP-1012 , placebo group . In treatment group , participant receive 0.5 mg TVP-1012 , 1 mg TVP-1012 , placebo daily double-blinded manner .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>The participant diagnosis Parkinson 's disease accord diagnostic criterion UK Parkinson 's Disease Society Brain Bank . The participant Modified Hoehn &amp; Yahr stage 2 4 ( `` Off '' state ) . The participant wearing phenomenon continuously receive levodopa combination drug &gt; = 6 month . The participant receive levodopa combination drug without change dose regimen ( dose frequency , least 3 time day ) . The participant receive entacapone stable dose regimen . The participant receive dopamine agonist , anticholinergic drug , amantadine , droxidopa , istradefylline , zonisamide stable dose regimen . The participant outpatient either sex age &gt; = 30 &lt; 80 year . The participant complete patient diary least 4 7 day . The participant mean daily offtime &gt; = 2.5 hour The participant unstable systemic disease . The participant severe dyskinesia . The participant MiniMental State Examination ( MMSE ) score &lt; = 24 . The participant major depression severe depression , clinically significant psychiatric disease . The participant history clinically significant hypertension reaction associate ingestion tyraminerich food . The participant receive neurosurgical intervention Parkinson 's disease ( e.g. , pallidotomy , thalamotomy , deep brain stimulation ) . The participant receive transcranial magnetic stimulation within 6 month . The participant receive selegiline , pethidine , tramadol , reserpine methyldopa within 90 day . The participant receive single agennt levodopa , psychoneurotic agent antiemetic medication dopamine agonist within 14 day . However , participant receive quetiapine domperidone stable dose regimen &gt; = 14 day may include study . The participant require take excluded medication treatment . The participant laboratory data meeting following : Creatinine &gt; = 2 x upper limit normal ( ULN ) Total bilirubin &gt; = 2 x ULN ALT AST &gt; = 1.5 x ULN ALP &gt; = 3 x ULN The participant receive excludeded medication treatment .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>